

WHO Expert Committee on Biological Standardization

Sixty-ninth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: www.who.int/bookorders).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 1 6

WHO Expert Committee on Biological Standardization

Sixty-ninth report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Expert Committee on Biological Standardization: sixty-ninth report
(WHO Technical Report Series, No. 1016)
ISBN 9 789241 210256
ISSN 0512-3054

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Biological Standardization: sixty-ninth report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1016). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Malta

Contents

Abbreviations	xii
1. Introduction	1
2. General	3
2.1 Current directions	3
2.1.1 Strategic directions in the regulation of medicines and other health technologies: WHO priorities	3
2.1.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization	5
2.1.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization	7
2.1.4 WHO comprehensive plan for the blood programme	8
2.2 Reports	10
2.2.1 Report from the WHO Blood Regulators Network	10
2.2.2 Report from the WHO network of collaborating centres on standardization and regulatory evaluation of vaccines	11
2.3 Feedback from custodian laboratories	13
2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations	13
2.4 Cross-cutting activities of other WHO committees and groups	19
2.4.1 Update from the WHO Expert Committee on Specifications for Pharmaceutical Preparations	19
2.4.2 Report of the 67th WHO International Nonproprietary Names Consultation: update on nomenclature for advanced therapies	19
2.4.3 Update from the WHO National Control Laboratory Network for Biologicals	20
2.4.4 Update from the WHO Product Development for Vaccines Advisory Committee	21
2.4.5 Update on immunization policy from the Strategic Advisory Group of Experts on Immunization	22
2.4.6 Progress report on the WHO pilot procedure for the prequalification of biotherapeutic products and SBPs	24
2.4.7 WHO Global model regulatory framework for medical devices including in vitro diagnostic medical devices	26
2.4.8 First meeting of the Strategic Advisory Group of Experts on In Vitro Diagnostics	27
3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological substances	29
3.1 General	29
3.1.1 Revision of the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards	29
3.1.2 WHO Vero reference cell bank 10-87	30
3.1.3 Deletion of the innocuity/abnormal toxicity test for biological products	32

3.2	Biotherapeutics other than blood products	33
3.2.1	WHO Questions and Answers: similar biotherapeutic products	33
3.3	Cellular and gene therapies	34
3.3.1	Update on cellular and gene therapies	34
3.4	Vaccines and related substances	35
3.4.1	Recommendations to assure the quality, safety and efficacy of recombinant hepatitis E vaccines	35
3.4.2	Guidelines for the safe development and production of vaccines to human pandemic influenza viruses and influenza viruses with pandemic potential	37
3.4.3	Guidelines for the safe production and quality control of poliomyelitis vaccines	38
3.4.4	Revision of the WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated)	40
3.4.5	International collaborative study to assess the utility of deep sequencing of virus stocks used in the manufacture of oral poliomyelitis vaccine	41
3.4.6	Revision of the WHO Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories	43
4.	International reference materials – antibiotics	45
4.1	WHO International Standards and Reference Reagents – antibiotics	45
4.1.1	Third WHO International Standard for erythromycin	45
5.	International reference materials – blood products and related substances	47
5.1	WHO International Standards and Reference Reagents – blood products and related substances	47
5.1.1	Second WHO International Standard for blood coagulation factor V (plasma, human)	47
5.1.2	Third WHO International Standard for anti-D immunoglobulin (human)	48
5.2	Proposed new projects and updates – blood products and related substances	49
5.2.1	Proposed First WHO International Standard for unfractionated heparin for molecular weight calibration	49
5.2.2	Proposed Third WHO International Standard for von Willebrand factor concentrate	50
5.2.3	Update on the WHO snakebite antivenom project	51
6.	International reference materials – cellular and gene therapies	53
6.1	Proposed new projects and updates – cellular and gene therapies	53
6.1.1	Proposed First WHO International Reference Reagent for mesenchymal stromal cell identity for flow cytometry	53
7.	International reference materials – in vitro diagnostics	55
7.1	WHO International Standards and Reference Reagents – in vitro diagnostics	55
7.1.1	First WHO International Reference Reagent for CD4+ T-cells (human)	55
7.1.2	First WHO International Reference Panel for HIV-1 p24 antigen and First WHO International Reference Reagent for HIV-2 p26 antigen	57
7.1.3	First WHO International Reference Reagent for von Willebrand factor (plasma) binding to recombinant glycoprotein Ib	58

7.1.4	Second WHO International Standard for prostate specific antigen (free) and Second WHO International Standard for prostate specific antigen (human) (total: PSA-ACT + free PSA)	60
7.1.5	Second WHO International Standard for HIV-2 RNA for NAT-based assays	61
7.1.6	First WHO International Standard for adenovirus DNA for NAT-based assays	62
7.2	Proposed new projects and updates – in vitro diagnostics	64
7.2.1	Proposed additional WHO international reference reagents for blood group genotyping	64
7.2.2	Proposed First WHO international standards for (cell line name) cancer genomes	65
7.2.3	Proposed First WHO international standards for <i>PIK3CA</i> variants	66
7.2.4	Proposed Second WHO International Standard for insulin-like growth factor-I (human, recombinant)	67
7.2.5	Proposed WHO international standards for enterovirus RNA for NAT-based assays	68
7.2.6	Proposed Fourth WHO International Standard for ferritin (human, recombinant)	69
7.2.7	Proposed First WHO International Reference Panel for microsatellite instability	70
7.2.8	Proposed First WHO International Standard for <i>Mycobacterium tuberculosis</i> DNA for NAT-based assays	71
7.2.9	Proposed First WHO International Standard for anti-thyroid peroxidase antibodies	72
7.2.10	Proposed extension of the First WHO International Reference Panel for HIV-1 circulating recombinant forms RNA for NAT-based assays	73
7.2.11	Proposed First WHO international standards for circulating tumour DNA	74
7.2.12	Proposed First WHO Reference Reagent for <i>Babesia microti</i> DNA for NAT-based assays	75
7.2.13	Update on the development of WHO international reference preparations for <i>Plasmodium vivax</i>	76
8.	International reference materials – standards for use in public health emergencies	78
8.1	WHO International Standards and Reference Reagents – standards for use in public health emergencies	78
8.1.1	First WHO International Standard for anti-Asian lineage Zika virus antibody (human)	78
8.2	Proposed new projects and updates – standards for use in public health emergencies	79
8.2.1	Proposed First WHO International Reference Reagent for MERS-CoV	79
8.2.2	Proposed WHO international standards for emerging and re-emerging viruses with epidemic potential	81
9.	International reference materials – vaccines and related substances	84
9.1	WHO International Standards and Reference Reagents – vaccines and related substances	84
9.1.1	Second WHO International Reference Cell Bank of MRC-5 cells	84
9.1.2	Seventh WHO International Standard for rabies vaccine	84
9.1.3	First WHO international standards for meningococcal serogroups W and Y polysaccharides	86

9.1.4	First WHO International Standard for Sabin inactivated poliomyelitis vaccine	87
9.2	Proposed new projects and updates – vaccines and related substances	89
9.2.1	Update on the development of influenza virus pathogenicity standards	89
9.2.2	Update on the development of the proposed First WHO International Standard for antibody to the influenza virus haemagglutinin stem domain	90
9.2.3	Proposed universal reagents for potency testing of inactivated poliomyelitis vaccines	91
9.2.4	Proposed First WHO International Standard for anti EV-D68 serum	92
Annex 1		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological substances used in medicine	95
Annex 2		
	Recommendations to assure the quality, safety and efficacy of recombinant hepatitis E vaccines	101
Annex 3		
	Guidelines for the safe development and production of vaccines to human pandemic influenza viruses and influenza viruses with pandemic potential	
	Replacement of Annex 5 of WHO Technical Report Series, No. 941; and the WHO 2009 A(H1N1) update; and the WHO 2013 A(H7N9) update	165
Annex 4		
	Guidelines for the safe production and quality control of poliomyelitis vaccines	
	Replacement of Annex 2 of WHO Technical Report Series, No. 926	209
Annex 5		
	Biological substances: WHO International Standards, Reference Reagents and Reference Panels	249

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>